RET (Protein|Antibody|cDNA Clone|ELISA Kit)

All RET reagents are produced in house and quality controlled, including 3 RET Antibody, 15 RET Gene, 2 RET Lysate, 2 RET Protein, 1 RET qPCR. All RET reagents are ready to use.

Recombinant RET proteins are expressed by Baculovirus-Insect Cells, HEK293 Cells with fusion tags as N-GST & His, C-His.

RET antibodies are validated with different applications, which are ELISA.

RET cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each RET of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.

RET Protein (2)


RET Protein, Human, Recombinant (His Tag)


Expression host: HEK293 Cells

Human RET Protein 9928

RET Protein, Human, Recombinant (aa 658-1114, His & GST Tag)


Expression host: Baculovirus-Insect Cells

Human RET Protein 9929

RET Antibody (3)


Anti-RET Antibody


Specificity: Human

Application: ELISA

Clonality: PAb

Anti-RET Antibody


Specificity: Human

Application: ELISA

Clonality: PAb

Anti-RET Antibody


Specificity: Human

Application: ELISA

Clonality: MAb


RET cDNA Clone (15)


RET qPCR Primer (1)

RET Lysate (2)

RET proto-oncogene, also known as RET, is a cell-surface molecule that transduce signals for cell growth and differentiation. It contains 1 cadherin domain and 1 protein kinase domain. RET proto-oncogene belongs to the protein kinase superfamily, tyr protein kinase family. RET proto-oncogene is involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. It phosphorylates PTK2/FAK1 and regulates both cell death/survival balance and positional information. RET is required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life; promotes the formation of Peyer's patch-like structures; modulates cell adhesion via its cleavage; involved in the development of the neural crest. RET proto-oncogene is active in the absence of ligand, triggering apoptosis. RET acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. It also regulates nociceptor survival and size; triggers the differentiation of rapidly adapting (RA) mechanoreceptors; mediated several diseases such as neuroendocrine cancers. Defects in RET may cause colorectal cancer, hirschsprung disease type 1, medullary thyroid carcinoma, multiple neoplasia type 2B, susceptibility to pheochromocytoma, multiple neoplasia type 2A, thyroid papillary carcinoma and congenital central hypoventilation syndrome.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy